London Daily

Focus on the big picture.
Wednesday, Jul 09, 2025

MS charities decry UK postcode lottery for ‘life-changing’ drug

MS charities decry UK postcode lottery for ‘life-changing’ drug

Nearly 70,000 estimated to be missing out on drug available on NHS in Wales and Scotland
People with multiple sclerosis are paying up to £600 a month for a “life-changing” drug that is available on the NHS in Wales and Scotland but not in England.

Charities estimate that tens of thousands of people with MS are missing out on fampridine, which can improve a person’s ability to walk and reduce the risk of falling over.

They say the “postcode lottery” within Britain around access to the drug is “grossly unfair” to patients in England, who are being forced to live with MS’s very debilitating symptoms – which can include problems with vision, arm and leg movement, sensation and balance.

The senior Labour MP Dame Margaret Hodge has written to the health secretary, Sajid Javid, urging him to ensure that the medication is available to anyone who needs it.

Her intervention came after her constituent Steven Brooks’s ability to walk improved markedly after receiving fampridine as part of a clinical trial but whose health then declined when the trial ended and his hospital could not provide it.

“It is grossly unfair that people with MS are being denied access to fampridine – a potentially life-changing treatment – based purely on where they live in the UK,” said Phillip Anderson, the head of policy at the MS Society.

“MS is relentless, painful and disabling, but we know this treatment can make a significant difference to many people’s symptoms, including helping them to walk and manage MS fatigue.”

The disparity in access has arisen because the National Institute for Health and Care Excellence (Nice), which advises the government and NHS in England, believes fampridine does not represent value for money whereas its equivalent bodies in Wales and Scotland have recommended it.

The MS Society estimates that about 40,000 MS patients in England who would benefit from taking the drug cannot get it because of Nice’s ruling. About 200 people there have obtained it on the NHS and only after submitting an “individual funding request” – an appeal against being denied an expensive form of treatment – and showing they have exceptional need for it.

But the society says they represent only 0.5% of those who may enjoy a boost to their walking ability and quality of life if they could get fampridine on the NHS.

Biogen, which makes the medication, says an even larger number of people in England – about 65,000 – could improve their health if they could obtain the drug, and another 3,000 in Northern Ireland.

The MS Trust said patients were paying between £200 and £600 a month for the drug privately.

David Martin, the trust’s chief executive, said: “In England people with MS are being forced to make difficult choices on whether to pay for a medication that they could get for free in other parts of the UK. We at the MS Trust don’t think this is fair.

“We know that fampridine can make a difference to some people with MS who experience walking difficulties and the MS Trust would like to see fair access to this treatment across the UK.”

In her letter, Hodge asked Javid why NHS England had not been able to secure a discount on the cost of the drug from Biogen after the Scottish NHS agreed a deal to ensure its availability.

“It is not acceptable to find NHS England lagging behind and failing to offer access to fampridine for free. This failure has created a postcode lottery for MS sufferers that has severely impacted on the life of my constituent.”

Nice is updating its guidance on treating MS, which charities and patients hope will lead to the drug becoming free on the NHS in England. That is expected in 2022.

The Department of Health and Social Care said it sympathised with patients denied the drug but backed Nice’s judgment.

“We want all patients to have access to first-rate, innovative medicines and sympathise with those dealing with challenging conditions like multiple sclerosis,” a spokesperson said.

“Nice is world-renowned for its expertise in identifying effective treatments at a price that is fair to the NHS and taxpayers. They found there is currently not enough evidence on the effectiveness of this medicine compared to other effective treatments to recommend it for patients.

“We want to reassure people that Nice keeps its guidance under review. It’s currently reviewing its recommendations on fampridine and expects to publish updated guidelines next year.”
Newsletter

Related Articles

0:00
0:00
Close
BRICS Expands Membership with Indonesia and Ten New Partner Countries
Weinstein Victim’s Lawyer Says MeToo Movement Still Strong
U.S. Enacts Sweeping Tax and Spending Legislation Amid Trade Policy Shifts
Football Mourns as Diogo Jota and Brother André Silva Laid to Rest in Portugal
Labour Expected to Withdraw Support for Special Needs Funding Model
Leaked Audio Reveals Tory Aide Defending DEI Record
Elon Musk Founds a Party Following a Poll on X: "You Wanted It – You Got It!"
London Stock Exchange Faces Historic Low in Initial Public Offerings
A new online platform has emerged in the United Kingdom, specifically targeting Muslim men seeking virgin brides
Trump Celebrates Independence Day with B-2 Flyover and Signs Controversial Legislation
Boris Johnson Urges Conservatives to Ignore Farage
SNP Ordered to Update Single-Sex Space Guidance Within Days
Starmer Set to Reject Calls for Wealth Taxes
Stolen Century-Old Rolls-Royce Recovered After Hotel Theft
Macron Presses Starmer to Recognise Palestinian State
Labour Delayed Palestine Action Ban Over Riot Concerns
Swinney’s Tax Comments ‘Offensive to Scots’, Say Tories
High Street Retailers to Enforce Bans on Serial Shoplifters
Music Banned by Henry VIII to Be Performed After 500 Years
Steve Coogan Says Working Class Is Being ‘Ethnically Cleansed’
Home Office Admits Uncertainty Over Visa Overstayer Numbers
JD Vance Questions Mandelson Over Reform Party’s Rising Popularity
Macron to Receive Windsor Carriage Ride in Royal Gesture
Labour Accused of ‘Hammering’ Scots During First Year in Power
BBC Head of Music Stood Down Amid Bob Vylan Controversy
Corbyn Eyes Hard-Left Challenge to Starmer’s Leadership
London Tube Trains Suspended After Major Fire Erupts Nearby
Richard Kemp: I Felt Safer in Israel Under Attack Than in the UK
Cyclist Says Police Cited Human Rights Act for Riding No-Handed
China’s Central Bank Consults European Peers on Low-Rate Strategies
AI Raises Alarms Over Long-Term Job Security
Saudi Arabia Maintains Ties with Iran Despite Israel Conflict
Musk Battles to Protect Tesla Amid Trump Policy Threats
Air France-KLM Acquires Majority Stake in Scandinavian Airlines
UK Educators Sound Alarm on Declining Child Literacy
Shein Fined €40 Million in France Over Misleading Discounts
Brazil’s Lula Visits Kirchner During Argentina House Arrest
Trump Scores Legislative Win as House Passes Tax Reform Bill
Keir Starmer Faces Criticism After Rocky First Year in Power
DJI Launches Heavy-Duty Coaxial Quadcopter with 80 kg Lift Capacity
U.S. Senate Approves Major Legislation Dubbed the 'Big Beautiful Bill'
Largest Healthcare Fraud Takedown in U.S. History Announced by DOJ
Poland Implements Border Checks Amid Growing Migration Tensions
Political Dispute Escalates Between Trump and Musk
Emirates Airline Expands Market Share with New $20 Million Campaign
Amazon Reaches Milestone with Deployment of One Millionth Robot
US Senate Votes to Remove AI Regulation Moratorium from Domestic Policy Bill
Yulia Putintseva Calls for Spectator Ejection at Wimbledon Over Safety Concerns
Jury Deliberations in Diddy Trial Yield Partial Verdict in Serious Criminal Charges
House Oversight Committee Subpoenas Former Jill Biden Aide Amid Investigation into Alleged Concealment of President Biden's Cognitive Health
×